Skip to main content
Main navigation
Schizophrenia Foundations
Symptomatology
Patient Burden
Caregiver Perspectives
Psychopharmacology
Search
Main navigation
Schizophrenia Foundations
Symptomatology
Patient Burden
Caregiver Perspectives
Psychopharmacology
Search
Psychopharmacology
Can Peripherally Restricted Anticholinergics Like Trospium Reduce Risks?
Welcome to Schizophrenia Knowledge Base
This website is intended for healthcare professionals in the United States.
Yes, I am a US healthcare professional
No, I am not a US healthcare professional
CME: End of the Anticholinergic Era? Deprescribing with Confidence: Strategies for Safe Medication Changes (Module 3)
CME: End of the Anticholinergic Era? Measuring the Impact: Understanding Anticholinergic Burden (Module 2)
CME: I Love Muscarinic Control! Targeting the Muscarinic System in the Treatment of Schizophrenia
CME: End of the Anticholinergic Era? Breaking Down the Anticholinergic System: Risks and Realities (Module 1)
CME: Psychopharmacolojourney: A Look at How Far We Have Come and Where We Might Go
Schizophrenia Unfiltered, Part 3: Pathways to Novel Treatment
Ins and Outs of Antipsychotic Therapy for Schizophrenia
End of the Anticholinergic Era? Rationale and Evidence-Based Strategies for Deprescribing
CME: The Next Generation of Schizophrenia Treatment: Looking Beyond D2 and Exploring Novel Therapeutic Targets
Overcoming Challenges in Schizophrenia Treatment
Pagination
First page
« First
Previous page
‹ Previous
Page
1
Page
2
Current page
3
Page
4
Page
5
Next page
Next ›
Last page
Last »